The CEO's total reported compensation of $12.19 million in 2025 is materially elevated, driven primarily by a $6.02 million special retention grant that was layered on top of the regular $3.75 million performance equity award — together these equity grants alone exceed what would be expected for a CEO at a $2 billion healthcare services company. More importantly, the pay-for-performance alignment check fails: above-benchmark variable pay was awarded while ADUS's 3-year stock return of +23% trailed the company's own peer group median of +97% by nearly 74 percentage points, meaning shareholders received far less than peers while executives received elevated total pay. The incentive plan structure also raises quality concerns — all bonuses and equity grants are tied solely to a single internal Adjusted EBITDA target with no multi-year stock performance condition, meaning awards vest once a budget hurdle is crossed regardless of whether shareholders benefited relative to peers.

The proxy does not disclose auditor fees or PwC's tenure, so neither the non-audit fee ratio trigger nor the tenure trigger can be confirmed; per policy, the tenure trigger requires confirmed data to fire, and absent fee data there is no independence concern to evaluate, so the default FOR vote applies. PwC is a Big 4 firm appropriate for a $2B company.